Overview

Cortec is Germany’s pioneering commercial BCI developer, established in 2010 with a focus on clinical translation and wireless implant technology. The company advanced beyond pure research to pursue commercial neuroinformatics and neural device development, positioning itself as a European counterpoint to US-based competitors.

Brain Interchange System

The Brain Interchange system is a fully wireless, implantable closed-loop neurostimulation device designed for therapeutic applications rather than direct communication or motor control. The absence of percutaneous connectors eliminates infection risks and facilitates longer-term implantation without repeated surgical intervention.

Clinical Milestone

Cortec achieved first human implantation in July 2025 at Harborview Medical Center in Seattle, demonstrating successful technology transfer from Germany to the United States healthcare system. This milestone establishes Cortec as a viable international competitor with FDA regulatory engagement.

Therapeutic Focus

The company is pursuing NIH-funded stroke rehabilitation trials, targeting restoration of motor function in stroke patients through targeted brain stimulation guided by neural recordings. This application differs from communication BCIs, addressing a larger patient population with significant unmet clinical needs.

Market Position

As Germany’s first implantable BCI developer, Cortec demonstrates strong European neurotechnology expertise and establishes alternative technology pathways to the dominant US-based approaches.